Simcere Pharmaceutical Group (STU:S2P) Interest Expense: €-11.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:S2P Simcere Pharmaceutical Group Ltd STU:S2P
94 GF Score
Price €1.38
GF Value €1.16
View Full Analysis

What is Simcere Pharmaceutical Group Interest Expense?

Simcere Pharmaceutical Group STU:S2P -2.82% 94 Interest Expense is €-11.6 Mil as of Dec. 2025. GuruFocus rates STU:S2P with a GF Score™ of 94/100 and a GF Value™ of €1.16.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Simcere Pharmaceutical Group's interest expense for the six months ended in Dec. 2025 was € -5.7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-11.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Simcere Pharmaceutical Group's Operating Income for the six months ended in Dec. 2025 was € 83.2 Mil. Simcere Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2025 was € -5.7 Mil. Simcere Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2025 was 14.51. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Simcere Pharmaceutical Group  (STU:S2P) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Simcere Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2025 was €-5.7 Mil. Its Operating Income for the six months ended in Dec. 2025 was €83.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €9.4 Mil.

Simcere Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*83.173/-5.731
=14.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Simcere Pharmaceutical Group Interest Expense Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Interest Expense Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only -9.84 -4.66 -4.44 -9.12 -11.62

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 -3.01 -6.05 -5.86 -5.73
STU:S2P
94GF Score
Simcere Pharmaceutical Group Ltd STU:S2P
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-11.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-11.6 Mil mean?
Simcere Pharmaceutical Group (STU:S2P) has a Interest Expense of €-11.6 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Interest Expense too high?
Simcere Pharmaceutical Group's current Interest Expense is €-11.6 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Interest Expense compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Interest Expense of €-11.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Interest Expense is €-11.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current Interest Expense of €-11.6 Mil. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current Interest Expense is €-11.6 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current Interest Expense is €-11.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.

Key valuation signals for STU:S2P:

  • Interest Expense: €-11.6 Mil
  • GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong Kong
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for STU:S2P

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38
Price
€1.16
GF Value